2-hydroxygarvin A | 99457-97-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 2-hydroxygarvin A
• 英文别名: methyl 7,9-dihydroxy-3-methoxy-5,5,7-trimethyl-6,8-dioxo-1-propylanthracene-2-carboxylate
• CAS: 99457-97-3
• 化学式: C₂₃H₂₆O₇
• 分子量: 414.455
• InChiKey: PRAZMVBMBFPZFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 2-hydroxygarvin A 在 吡啶 作用下， 以4 mg的产率得到7,9-Diacetoxy-3-methoxy-5,5,7-trimethyl-6,8-dioxo-1-propyl-5,6,7,8-tetrahydro-anthracene-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Metabolites of the marine hydroid Garveia annulata: garveatins B and C, 2-hydroxygarvin A, and garvin A quinone

  摘要：

  DOI：

  10.1021/jo00351a010

文献信息

• [EN] INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS<br/>[FR] INHIBITEURS DE LA INDOLEAMINE 2,3-DIOXYGENASE (IDO)
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2006005185A1

  公开（公告）日：2006-01-19

  Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacteria/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.

  提供了吲哚胺2,3-二氧化酶（IDO）的抑制剂，包括含有这些抑制剂的药物组合物，以及利用这些抑制剂和组合物治疗哺乳动物主体中的一种病况的用途，该病况的特征是IDO介导的色氨酸代谢通路的病理。这些病况可能涉及抑制T细胞介导的免疫应答，或者可能直接由色氨酸耗竭或色氨酸降解产物积累导致。具体的疾病条件包括白内障、眼睛的老化黄斑、神经退行性疾病、情绪障碍、癌症以及各种细菌/病毒感染。本发明的IDO抑制剂是取代萘和蒽二酮。本发明的新化合物包括以下的牛磺酸取代萘醌结构。
• Annulins A, B, C or analogs as indoleamine 2,3-dioxygenase (IDO) inhibitors for treatment of cancer
  申请人：THE UNIVERSITY OF BRITISH COLUMBIA

  公开号：EP2130826A1

  公开（公告）日：2009-12-09

  Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cancer. IDO inhibitors of this invention are homologs of annulin A, annulin B or annulin C.

  本研究提供了吲哚胺 2,3-二氧化酶（IDO）的抑制剂以及含有此类抑制剂的药物组合物，还提供了使用此类抑制剂和组合物治疗哺乳动物体内以 IDO 介导的色氨酸代谢途径病理学为特征的疾病的方法。此类病症可能涉及抑制 T 细胞介导的免疫反应，也可能直接导致色氨酸耗竭或色氨酸降解产物的积累。具体的疾病情况包括癌症。本发明的 IDO 抑制剂是鹅膏素 A、鹅膏素 B 或鹅膏素 C 的同源物。
• EP1773846A4
  申请人：——

  公开号：EP1773846A4

  公开（公告）日：2008-10-08
• INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
  申请人：THE UNIVERSITY OF BRITISH COLUMBIA

  公开号：EP1773846A1

  公开（公告）日：2007-04-18
• Indoleamine 2,3-Dioxygenase (IDO) Inhibitors
  申请人：ANDERSEN Raymond J.

  公开号：US20090042868A1

  公开（公告）日：2009-02-12

  Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.